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Abstract
Introduction Ewing sarcoma family of tumour represents a
group of bone and soft-tissue tumours with variable neu-
roectodermal differentiation. Extraosseous Ewing sarcoma
(EES) commonly arises in soft tissues of trunk or
extremities with a few reported rare sites include larynx,
nasal cavity, neck, lung, retroperitoneum, mediastinum and
genital tract. Till now 28 cases of extraosseous Ewing
sarcoma of vulva and vagina have been reported in the
literature.
Case Report We report 29th case of Ewing sarcoma vulva
in sixth youngest, 16-year-old patient with third largest size
tumour. Her all routine blood reports were found to be
normal, and MRI showed highly vascular vulval mass with
terminal urethral involvement. Tru-cut biopsy revealed
uniform sheets of small round cells with geographical
necrosis and perivascular clusters of tumour cells.
Immunohistochemical staining demonstrated that the cells
were focally positive for CK and vimentin and showed
membranous positivity for CD99 and nuclear positivity for
FLI1, whereas all other IHC markers to rule out differen-
tials of small round cell tumour were negative. Based on
HPE and IHC, which is polyimmunophenotypic, has con-
firmed the diagnosis of an ES/PNET. After ruling out for
the metastatic lesions, 14 cycles of chemotherapy with
compressed VDC/IE were planned, but after receiving her
1st cycle itself, she expired on 10th day of post-
chemotherapy.
Conclusion EES is a rare fast growing aggressive tumour
requiring ancillary techniques for exact diagnosis and
multimodality treatment for better survival.
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Introduction
Ewing sarcoma family of tumour (ESFT) represents a
group of bone and soft-tissue tumours with variable
neuroectodermal differentiation where Ewing sarcoma
(ES) is typically undifferentiated, and primitive neuroec-
todermal tumour (PNET) shows a clear evidence of neural
differentiation. Though they are aggressive round cell
tumour, they are highly chemosensitive. Hence, their
identification by pathologist is crucial with the help of
immunohistochemistry (IHC) and molecular ancillary
techniques.
To our knowledge, very few cases of extraosseous
Ewing sarcoma (EES)/PNET have previously been repor-
ted in the English literature and they behave not in a dif-
ferent way from skeletal ESFT. We present a case of
primary Ewing sarcoma of vulva of an adolescent.
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Case Report
A 16-year-old adolescent girl came to our OPD with a
rapidly growing vulval mass for the last 1 month with
severe pain. On examination a 15 9 10 cm vulval mass
seen on the left side with no ulceration and intact skin. On
investigations all her blood reports were found to be nor-
mal, and MRI showed highly vascular vulval mass with
terminal urethral involvement. FNAC was inconclusive.
She was then taken up for tissue biopsy. Histopathological
examination showed uniform sheets of small round cells
with scanty, indistinct cytoplasmic outline, round nuclei
with fine chromatin and inconspicuous nucleoli. Geo-
graphical necrosis and perivascular clusters of tumour cells
are seen. A diagnosis of round cell tumour of vulva was
offered, and IHC was recommended. Immunohistochemi-
cal staining demonstrated that the cells were focally posi-
tive for CK and vimentin and showed membranous
positivity for CD99 and nuclear positivity for FLI1, while
negative for terminal deoxyribonucleotidyl transferase
(TdT), myogenin, desmin and CD34. This combination of
HPE and IHC which is polyimmunophenotypic has con-
firmed the diagnosis of an ES/PNET (Figs. 1, 2, 3).
The patient was referred for treatment to a paediatric
oncologist. CT and MRI studies were negative for metas-
tasis. A bone marrow biopsy was performed that was
negative for ES. Fourteen cycles of chemotherapy with
compressed VDC/IE (vincristine, doxorubicin, cyclophos-
phamide/ifosfamide and etoposide) were planned, but after
receiving her 1st cycle, she expired on 10th day of post-
chemotherapy.
Discussion
Ewing sarcoma is the second most common bone and soft-
tissue (15%) sarcoma in children. Extraosseous Ewing sar-
coma (EES) commonly arises in soft tissues of trunk or
extremities, especially chest wall and paravertebral region,
but a few reported rare sites include larynx, nasal cavity, neck,
lung, retroperitoneum, perineum and mediastinum [1–3].
The first case series of round cell neoplasms mimicing
Ewing sarcoma of bone was documented by Tefft et al.
(1969) in paravertebral region, but later in 1975 Angervall
and Enzinger termed these type of tumour as extraskeletal
Ewing sarcoma (EES) [4].
EES/PNET of the female genital tract (FGT) is very
unusual, and reported most common sites in FGT were the
ovaries [5] followed by the uterine body [6] and less
commonly the cervix [7], vagina and vulva [8, 9].
After thorough literature search, we could identify 28
cases of extraosseous Ewing sarcoma of vulva and vagina
with molecular diagnosis in seven to eight cases [10].
The median age of the reported cases was 27 year with
an age range from 10 to 52 years. The average size of the
tumour was 5.8 cm (SD 5.03 cm). Eleven cases presented
with metastatic disease and had poor survival.
The present case was supposed to be the third largest in
size, in sixth youngest patient who was clinically diagnosedFig. 1 Sixteen-year-old girl presented with huge vulval mass
Fig. 2 H&E, 40X, sheets of small blue round cell tumour
Fig. 3 IHC, 40X, nuclear positivity of FLI1
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as rhabdomyosarcoma. The swelling was painful and fast
growing like most of the reported cases.
The differential diagnosis of these tumours includes
other small round blue cell tumours such as rhab-
domyosarcoma, neuroblastoma (in children), lymphoma,
small cell carcinoma (primary or metastatic), melanoma,
cutaneous adnexal tumours and Merkel cell carcinoma.
The exact diagnosis of EES relies on histopathology
along with ancillary techniques like immunohistochemistry
and cytogenetic analysis, reverse transcriptase polymerase
chain reaction and fluorescence in situ hybridisation.
Immunohistochemical demonstration of CD99/MIC 2,
which is a cell membrane glycoprotein and intranuclear
FLI1, was indicative of ES/PNET.
While negative desmin and MyoD1 ruled out a rhab-
domyosarcoma, negative epithelial and neuroendocrine
marker rules out possibility of small cell carcinoma and
merkel cell carcinoma, and lacking of LCA positivity rules
out lymphoma.
Demonstration of t(11;22)(q24;q12) chromosomal
translocation (EWS-FLI1 gene rearrangement) is highly
specific for ES/PNET since it is seen in more than 90% of
the tumours.
It would be worth mentioning about the finding of Xiao
et al. [9] that serum CA125 may be an important marker for
prognosis and follow-up of PNET of the female genital
tract as amongst their 11 cases, the CA125 levels of 8
patients were elevated before treatment and fell markedly
to the normal when the disease was controlled although the
level does not correlate with the severity of the disease.
Literature suggested that EES had more aggressive
behaviour and a worse prognosis than the bony counterpart,
with reported five-year survival rate for skeletal Ewing
sarcoma around 75% as compared to 38% in the
extraskeletal counterpart. But there were available litera-
ture reporting relatively favourable outcome for extraoss-
eous ES/PNET arising in cutaneous and other superficial
site. Hence, prognosis basically depends on tumour size,
superficial location, early detection, metastasis and com-
plete surgical removal of the lesion [1].
Since the present case had very large mass with
involvement of urethra, surgery was not possible, and after
post-chemotherapy, patient died of tumour lysis syndrome
although there was no obvious metastasis at the time of
presentation.
Being so aggressive in nature, these tumours would
require multimodal treatment strategies. Current treatment
modality for PNET includes surgical resection whenever
feasible and adjuvant chemotherapy, which was thought to
play an important role in the management [9]. Role of
radiotherapy is not known for the reported cases at these
sites.
Conclusion
EES is a rare fast growing aggressive tumour affecting
young females. Exact diagnosis requires ancillary tech-
niques such as IHC and molecular cytogenetics along with
routine H&E. Early diagnosis and multimodality treatment
are necessary along with follow-up for survival benefit.
CA-125 may play a role in prognosis and follow-up, for
that more and more studies are required.
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